Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-10.80% $5.50
America/New_York / 20 mar 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 120.98 mill |
EPS: | -20.63 |
P/E: | -0.267 |
Earnings Date: | Aug 09, 2023 |
SharesOutstanding: | 22.00 mill |
Avg Daily Volume: | 0.0053 mill |
RATING 2023-05-17 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Neutral | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Buy | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | ||
Gr.Profit | n/a | n/a | n/a | n/a | ||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.267 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.05x |
Company: PE -0.267 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.08 - 3.32 ( +/- 22.89%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-11 | Wilson Robert N | Buy | 506 | Common Stock |
2023-11-07 | Leheny A. Rachel | Buy | 2 000 | Common Stock |
2023-11-06 | Roberts Eric W | Buy | 2 400 | Common Stock |
2023-11-03 | Roberts Eric W | Buy | 11 249 | Common Stock |
2023-11-03 | Roberts Eric W | Buy | 3 700 | Common Stock |
INSIDER POWER |
---|
96.28 |
Last 97 transactions |
Buy: 3 103 303 | Sell: 60 672 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $5.50 (-10.80% ) |
Volume | 0.0246 mill |
Avg. Vol. | 0.0053 mill |
% of Avg. Vol | 466.70 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.